메뉴 건너뛰기




Volumn 69, Issue 11, 2017, Pages 1399-1406

Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure

Author keywords

acute heart failure; decongestion; outcomes; strategies; volume overload

Indexed keywords

FUROSEMIDE; PLACEBO; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

EID: 85015226208     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.004     Document Type: Article
Times cited : (168)

References (27)
  • 1
    • 77957227912 scopus 로고    scopus 로고
    • Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology
    • 1 Gheorghiade, M., Follath, F., Ponikowski, P., et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 12 (2010), 423–433.
    • (2010) Eur J Heart Fail , vol.12 , pp. 423-433
    • Gheorghiade, M.1    Follath, F.2    Ponikowski, P.3
  • 2
    • 59649118099 scopus 로고    scopus 로고
    • Importance of venous congestion for worsening of renal function in advanced decompensated heart failure
    • 2 Mullens, W., Abrahams, Z., Francis, G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 (2009), 589–596.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 589-596
    • Mullens, W.1    Abrahams, Z.2    Francis, G.S.3
  • 3
    • 84875165977 scopus 로고    scopus 로고
    • Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial
    • 3 Ambrosy, A.P., Pang, P.S., Khan, S., et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 34 (2013), 835–843.
    • (2013) Eur Heart J , vol.34 , pp. 835-843
    • Ambrosy, A.P.1    Pang, P.S.2    Khan, S.3
  • 4
    • 84899473065 scopus 로고    scopus 로고
    • Decongestion in acute heart failure
    • 4 Mentz, R.J., Kjeldsen, K., Rossi, G.P., et al. Decongestion in acute heart failure. Eur J Heart Fail 16 (2014), 471–482.
    • (2014) Eur J Heart Fail , vol.16 , pp. 471-482
    • Mentz, R.J.1    Kjeldsen, K.2    Rossi, G.P.3
  • 5
    • 84890369206 scopus 로고    scopus 로고
    • Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial
    • 5 Chen, H.H., Anstrom, K.J., Givertz, M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310 (2013), 2533–2543.
    • (2013) JAMA , vol.310 , pp. 2533-2543
    • Chen, H.H.1    Anstrom, K.J.2    Givertz, M.M.3
  • 6
    • 84871058843 scopus 로고    scopus 로고
    • Ultrafiltration in decompensated heart failure with cardiorenal syndrome
    • 6 Bart, B.A., Goldsmith, S.R., Lee, K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 (2012), 2296–2304.
    • (2012) N Engl J Med , vol.367 , pp. 2296-2304
    • Bart, B.A.1    Goldsmith, S.R.2    Lee, K.L.3
  • 7
    • 11144355788 scopus 로고    scopus 로고
    • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    • 7 Gheorghiade, M., Gattis, W.A., O'Connor, C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004), 1963–1971.
    • (2004) JAMA , vol.291 , pp. 1963-1971
    • Gheorghiade, M.1    Gattis, W.A.2    O'Connor, C.M.3
  • 8
    • 33947713810 scopus 로고    scopus 로고
    • Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    • 8 Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
    • (2007) JAMA , vol.297 , pp. 1319-1331
    • Konstam, M.A.1    Gheorghiade, M.2    Burnett, J.C.3
  • 9
    • 33947719178 scopus 로고    scopus 로고
    • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    • 9 Gheorghiade, M., Konstam, M.A., Burnett, J.C. Jr., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007), 1332–1343.
    • (2007) JAMA , vol.297 , pp. 1332-1343
    • Gheorghiade, M.1    Konstam, M.A.2    Burnett, J.C.3
  • 10
    • 70349464874 scopus 로고    scopus 로고
    • Effects of tolvaptan on dyspnoea relief from the EVEREST trials
    • 10 Pang, P.S., Konstam, M.A., Krasa, H.B., et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 30 (2009), 2233–2240.
    • (2009) Eur Heart J , vol.30 , pp. 2233-2240
    • Pang, P.S.1    Konstam, M.A.2    Krasa, H.B.3
  • 11
    • 84878580083 scopus 로고    scopus 로고
    • Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan
    • 11 Hauptman, P.J., Burnett, J., Gheorghiade, M., et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 19 (2013), 390–397.
    • (2013) J Card Fail , vol.19 , pp. 390-397
    • Hauptman, P.J.1    Burnett, J.2    Gheorghiade, M.3
  • 12
    • 84953343125 scopus 로고    scopus 로고
    • Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials
    • 12 Felker, G.M., Mentz, R.J., Adams, K.F., et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail 8 (2015), 997–1005.
    • (2015) Circ Heart Fail , vol.8 , pp. 997-1005
    • Felker, G.M.1    Mentz, R.J.2    Adams, K.F.3
  • 13
    • 79952260198 scopus 로고    scopus 로고
    • Diuretic strategies in patients with acute decompensated heart failure
    • 13 Felker, G.M., Lee, K.L., Bull, D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 (2011), 797–805.
    • (2011) N Engl J Med , vol.364 , pp. 797-805
    • Felker, G.M.1    Lee, K.L.2    Bull, D.A.3
  • 14
    • 79960090547 scopus 로고    scopus 로고
    • Effect of nesiritide in patients with acute decompensated heart failure
    • 14 O'Connor, C.M., Starling, R.C., Hernandez, A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
    • (2011) N Engl J Med , vol.365 , pp. 32-43
    • O'Connor, C.M.1    Starling, R.C.2    Hernandez, A.F.3
  • 15
    • 77957730950 scopus 로고    scopus 로고
    • Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure
    • 15 Massie, B.M., O'Connor, C.M., Metra, M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363 (2010), 1419–1428.
    • (2010) N Engl J Med , vol.363 , pp. 1419-1428
    • Massie, B.M.1    O'Connor, C.M.2    Metra, M.3
  • 16
    • 84871986523 scopus 로고    scopus 로고
    • Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
    • 16 Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
    • (2013) Lancet , vol.381 , pp. 29-39
    • Teerlink, J.R.1    Cotter, G.2    Davison, B.A.3
  • 17
    • 84962124728 scopus 로고    scopus 로고
    • Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction
    • 17 Matsue, Y., Suzuki, M., Torii, S., et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22 (2016), 423–432.
    • (2016) J Card Fail , vol.22 , pp. 423-432
    • Matsue, Y.1    Suzuki, M.2    Torii, S.3
  • 18
    • 84877305602 scopus 로고    scopus 로고
    • Markers of decongestion, dyspnea relief and clinical outcomes among patients hospitalized with acute heart failure
    • 18 Kociol, R.D., McNulty, S.E., Hernandez, A.F., et al. Markers of decongestion, dyspnea relief and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 6 (2013), 240–245.
    • (2013) Circ Heart Fail , vol.6 , pp. 240-245
    • Kociol, R.D.1    McNulty, S.E.2    Hernandez, A.F.3
  • 19
    • 41149148032 scopus 로고    scopus 로고
    • A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
    • 19 Pang, P.S., Cleland, J.G., Teerlink, J.R., et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 29 (2008), 816–824.
    • (2008) Eur Heart J , vol.29 , pp. 816-824
    • Pang, P.S.1    Cleland, J.G.2    Teerlink, J.R.3
  • 20
    • 84901694452 scopus 로고    scopus 로고
    • Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation
    • 20 Miller, W.L., Mullan, B.P., Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation. J Am Coll Cardiol HF 2 (2014), 298–305.
    • (2014) J Am Coll Cardiol HF , vol.2 , pp. 298-305
    • Miller, W.L.1    Mullan, B.P.2
  • 21
    • 84955196189 scopus 로고    scopus 로고
    • In-hospital worsening heart failure
    • 21 Butler, J., Gheorghiade, M., Kelkar, A., et al. In-hospital worsening heart failure. Eur J Heart Fail 17 (2015), 1104–1113.
    • (2015) Eur J Heart Fail , vol.17 , pp. 1104-1113
    • Butler, J.1    Gheorghiade, M.2    Kelkar, A.3
  • 22
    • 84929458511 scopus 로고    scopus 로고
    • Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies
    • 22 Davison, B.A., Metra, M., Cotter, G., et al. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. J Am Coll Cardiol HF 3 (2015), 395–403.
    • (2015) J Am Coll Cardiol HF , vol.3 , pp. 395-403
    • Davison, B.A.1    Metra, M.2    Cotter, G.3
  • 23
    • 84939563068 scopus 로고    scopus 로고
    • Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)
    • 23 Kelly, J.P., Mentz, R.J., Hasselblad, V., et al. Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). Am Heart J 170 (2015), 298–305.
    • (2015) Am Heart J , vol.170 , pp. 298-305
    • Kelly, J.P.1    Mentz, R.J.2    Hasselblad, V.3
  • 24
    • 84859634464 scopus 로고    scopus 로고
    • Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function
    • 24 Metra, M., Davison, B., Bettari, L., et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5 (2012), 54–62.
    • (2012) Circ Heart Fail , vol.5 , pp. 54-62
    • Metra, M.1    Davison, B.2    Bettari, L.3
  • 25
    • 84881106998 scopus 로고    scopus 로고
    • Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion
    • 25 Testani, J.M., Brisco, M.A., Chen, J., McCauley, B.D., Parikh, C.R., Tang, W.H., Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 62 (2013), 516–524.
    • (2013) J Am Coll Cardiol , vol.62 , pp. 516-524
    • Testani, J.M.1    Brisco, M.A.2    Chen, J.3    McCauley, B.D.4    Parikh, C.R.5    Tang, W.H.6
  • 26
    • 79960426743 scopus 로고    scopus 로고
    • Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
    • 26 Irazabal, M.V., Torres, V.E., Hogan, M.C., et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80 (2011), 295–301.
    • (2011) Kidney Int , vol.80 , pp. 295-301
    • Irazabal, M.V.1    Torres, V.E.2    Hogan, M.C.3
  • 27
    • 84888646403 scopus 로고    scopus 로고
    • Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease
    • 27 Boertien, W.E., Meijer, E., de Jong, P.E., et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 84 (2013), 1278–1286.
    • (2013) Kidney Int , vol.84 , pp. 1278-1286
    • Boertien, W.E.1    Meijer, E.2    de Jong, P.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.